Addex Therapeutics (ADXN) SEC Filings & 10K Form $9.51 +0.27 (+2.92%) Closing price 09/25/2025 03:50 PM EasternExtended Trading$8.62 -0.89 (-9.36%) As of 09/25/2025 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share SEC Filings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Recent Addex Therapeutics SEC Filings All Filing Types 1 10 10-D 10-K 10-M 10-Q 11-K 12b-25 13F 13H 144 15 15F 17-H 18 18-K 19b-4(e) 19b-4 19b-7 1-A 1-E 1-K 1-N 1-SA 1-U 1-Z 20-F 24F-2 25 2-E 3 4 40-F 5 6-K 7-M 8-A 8-K 8-M 9-M ABS DD-15E ABS-15G ABS-EE ADV ADV-E ADV-H ADV-NR ADV-W ATS ATS-R BD BD-N BDW C CA-1 CB CFPORTAL D F-1 F-10 F-3 F-4 F-6 F-7 F-8 F-80 F-N F-X ID MA MA-I MA-NR MA-W MSD MSDW n/a N-14 N-17D-1 N-17f-1 N-17f-2 N-18f-1 N-1A N-2 N-23c-3 N-27D-1 N-3 N-4 N-5 N-54A N-54C N-6 N-6EI-1 N-6F N-8A N-8B-2 N-8B-4 N-8F N-CR N-CSR N-MFP N-PX N-Q NRSRO N-SAR PF PILOT R31 S-1 S-11 S-20 S-3 S-4 S-6 S-8 SBSE SBSE-A SBSE-BD SBSE-C SBSE-W SCI SD SDR SE SF-1 SF-3 SIP T-1 T-2 T-3 T-4 T-6 TA-1 TA-2 TA-W TCR TH WB-APP X-17A-19 X-17A-5 Part I X-17A-5 Part II X-17A-5 Part IIA X-17A-5 Part IIB X-17A-5 Part III X-17A-5 Schedule I X-17F-1A Filing Types Include Ownership Filings Exclude Ownership Filings Only Show Ownership FIlings Ownership Filings Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel DateFilerForm TypeView09/23/20255:09 AMAddex Therapeutics (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 06/30/20255:05 AMAddex Therapeutics (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 06/25/20255:05 AMAddex Therapeutics (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 06/20/20255:00 AMAddex Therapeutics (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 06/06/20255:05 AMAddex Therapeutics (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 05/12/20255:05 AMAddex Therapeutics (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 04/30/20255:05 AMAddex Therapeutics (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 04/25/20255:18 AMAddex Therapeutics (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 04/17/20255:05 AMAddex Therapeutics (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 11/22/20245:00 AMAddex Therapeutics (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 09/30/20245:01 AMAddex Therapeutics (Filer)Form 6-KReport of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 (Data available from 1/1/2016 forward) Related Companies and Tools Related Companies JSPR 10K Form XLO 10K Form PLUR 10K Form ATHE 10K Form DYAI 10K Form XFOR 10K Form SNTI 10K Form MRSN 10K Form PYRGF 10K Form KLTO 10K Form SEC Filings Tools Latest SEC FilingsInsider Trading Activity This page (NASDAQ:ADXN) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredChina Targets MAGA In Stealth Trade War TacticsChina is deliberately targeting the economic backbone of conservative America - The very industries that supp...Goldco Precious Metals | SponsoredCollege grad makes $64,000 a monthNothing hurts like a missed opportunity... And with AI stocks like Nvidia, Palantir, and Oracle continuing...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
